Outlook on the CAR-T Cell Therapies Industry - In-depth Review of the Various Patents and Affiliated IP Documents
25 avr. 2022 05h58 HE
|
Research and Markets
Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
Monthly information on share capital and company voting rights
07 avr. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Global $33+ Billion CAR-T Cell Therapy Markets, 2017-2021 & 2022-2027: Focus on Yescarta, Kymriah, Tecartus, Breyanzi, Abecma
05 avr. 2022 04h33 HE
|
Research and Markets
Dublin, April 05, 2022 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region,...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Conferences During April 2022
29 mars 2022 07h00 HE
|
Autolus Therapeutics plc
- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14th Kempen Life Sciences Conference on April 21 -...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
10 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
03 mars 2022 07h00 HE
|
Autolus Therapeutics plc
- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1 - Method for expressing stable low levels...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
21 févr. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
14 févr. 2022 05h43 HE
|
Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
Monthly information on share capital and company voting rights
11 févr. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...